WallStreetZenWallStreetZen

NYSEMKT: PHGE
Biomx Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Should I buy or sell PHGE stock?

Based on 1 analyst offering ratings for Biomx Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their PHGE stock forecasts and price targets.

PHGE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-09

1 of 1

Forecast return on equity

Is PHGE forecast to generate an efficient return?

Company
-7,912.82%
Industry
15.36%
Market
166.97%
PHGE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PHGE forecast to generate an efficient return on assets?

Company
-3,050.2%
Industry
23.16%
PHGE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PHGE earnings per share forecast

What is PHGE's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$12.48
Avg 2 year Forecast
-$13.24
Avg 3 year Forecast
-$12.80

PHGE revenue forecast

What is PHGE's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$14.1M+4,139.76%
PHGE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PHGE revenue growth forecast

How is PHGE forecast to perform vs Biotechnology companies and vs the US market?

Company
228.14%
Industry
32.4%
Market
13.27%
PHGE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PHGE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PHGE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PHGE$0.14N/AN/AHold
GRI$1.65$32.00+1,839.39%Buy
GLMD$4.31N/AN/A
XRTX$2.04N/AN/A
CLDI$1.34N/AN/A
View Top Biotech Stocks

Biomx Stock Forecast FAQ

Is Biomx Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: PHGE) stock is to Hold PHGE stock.

Out of 1 analyst, 0 (0%) are recommending PHGE as a Strong Buy, 0 (0%) are recommending PHGE as a Buy, 1 (100%) are recommending PHGE as a Hold, 0 (0%) are recommending PHGE as a Sell, and 0 (0%) are recommending PHGE as a Strong Sell.

If you're new to stock investing, here's how to buy Biomx stock.

What is PHGE's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSEMKT: PHGE) Biomx's current Earnings Per Share (EPS) is -$39.64. On average, analysts forecast that PHGE's EPS will be -$12.48 for 2026, with the lowest EPS forecast at -$18.25, and the highest EPS forecast at -$6.14. On average, analysts forecast that PHGE's EPS will be -$13.24 for 2027, with the lowest EPS forecast at -$19.55, and the highest EPS forecast at -$6.31. In 2028, PHGE's EPS is forecast to hit -$12.80 (min: -$20.11, max: -$4.80).

What is PHGE's forecast return on equity (ROE) for 2026-2029?

(NYSEMKT: PHGE) forecast ROE is -7,912.82%, which is considered weak.

What is PHGE's earnings growth forecast for 2026-2028?

(NYSEMKT: PHGE) Biomx's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.28%.

Biomx's earnings in 2026 is -$72,955,000.On average, 4 Wall Street analysts forecast PHGE's earnings for 2026 to be -$333,505,880, with the lowest PHGE earnings forecast at -$487,646,490, and the highest PHGE earnings forecast at -$164,151,371. On average, 4 Wall Street analysts forecast PHGE's earnings for 2027 to be -$353,813,349, with the lowest PHGE earnings forecast at -$522,478,382, and the highest PHGE earnings forecast at -$168,640,982.

In 2028, PHGE is forecast to generate -$341,955,968 in earnings, with the lowest earnings forecast at -$537,406,336 and the highest earnings forecast at -$128,234,490.

What is PHGE's revenue growth forecast for 2026-2028?

(NYSEMKT: PHGE) Biomx's forecast annual revenue growth rate of 228.14% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.4%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.27%.

Biomx's revenue in 2026 is $332,000.On average, 3 Wall Street analysts forecast PHGE's revenue for 2026 to be $0, with the lowest PHGE revenue forecast at $0, and the highest PHGE revenue forecast at $0. On average, 3 Wall Street analysts forecast PHGE's revenue for 2027 to be $0, with the lowest PHGE revenue forecast at $0, and the highest PHGE revenue forecast at $0.

In 2028, PHGE is forecast to generate $376,165,194 in revenue, with the lowest revenue forecast at $361,413,618 and the highest revenue forecast at $387,228,876.

What is PHGE's forecast return on assets (ROA) for 2026-2029?

(NYSEMKT: PHGE) forecast ROA is -3,050.2%, which is lower than the forecast US Biotechnology industry average of 23.16%.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.